INTRODUCTION {#S0001}
============

Chronic Obstructive Pulmonary Disease (COPD) is a progressive condition characterized by irreversible limitation of airflow ([@CIT0001]). COPD imposes a significant burden; in 2000, the World Health Organization (WHO) estimated that 2.47 million people died from COPD worldwide. It is projected that by 2020, COPD will become the third leading cause of death ([@CIT0002]). In the United Kingdom, COPD is the leading cause of chronic respiratory disease ([@CIT0003]). The main risk factor for developing COPD is smoking; others include air pollution, occupational exposure to chemical substances and dusts, poor nutritional status, alcohol consumption and alpha-1-antitrypsin deficiency ([@CIT0004]).

COPD primarily affects the lungs; however, various systemic complications including pulmonary hypertension ([@CIT0005], [@CIT0006]), cor pulmonale ([@CIT0007], [@CIT0008]), weight loss ([@CIT0009], [@CIT0010]), insulin resistance ([@CIT0011]), systemic inflammation ([@CIT0012]), depression ([@CIT0013], [@CIT0014]), and sleep disturbances ([@CIT0015]) have been linked to COPD.

An important and common systemic consequence of COPD is sleep disturbances characterized by insomnia and poor sleep quality. A rich body of subjective and objective evidence exist describing sleep disturbances in COPD patients ([@CIT0016]--[@CIT0019]). Sleep disorders and insomnia negatively affect the quality of life of COPD patients ([@CIT0020]). Administration of conventional sedative-hypnotic drugs (e.g. benzodiazepines) is not recommended in patients with respiratory failure, as these drugs may suppress ventilatory response and exacerbate sleep-related breathing disorders ([@CIT0021]).

Melatonin, an endogenous hormone synthesized and secreted into the systemic circulation and cerebrospinal fluid by the pineal gland ([@CIT0022]), is believed to play a cardinal role in regulating the circadian rhythm and sleeping during the night. Melatonin has been widely used to treat sleep disturbances and insomnias caused by aging and other specific pathologic conditions ([@CIT0023]--[@CIT0025]).

Given the principal role of melatonin in regulation of somnolence, we aimed to evaluate the efficacy of exogenous melatonin administration in improving sleep quality in COPD patients.

MATERIALS AND METHODS {#S0002}
=====================

In order to evaluate the effect of melatonin therapy on sleep quality of COPD patients, a randomized, double-blind, placebo controlled clinical trial was conducted in Respiratory Department of Shahid Sadoughi Hospital, Yazd, Iran. All patients had a stable condition and complained of sleep disorder. The exclusion criteria were as follows: ([@CIT0001]) history of COPD exacerbation in the past month ([@CIT0002]) presence of obstructive sleep apnea ([@CIT0003]) history of mental disorders known to affect sleep (e.g. anxiety and depression spectrum) ([@CIT0004]) prior use of sedative-hypnotic drugs ([@CIT0005]) use of nocturnal oxygen therapy.

Fifty-four patients with confirmed diagnosis of stage II to IV COPD based on Global Initiative for Chronic Obstructive Disease (GLOD) criteria ([@CIT0026]) were initially recruited in this study and were randomly assigned into two groups (melatonin and placebo). Forty-eight patients completed the study protocol. For patients in melatonin group, 3 mg melatonin was prescribed one hour before bedtime and the other group received placebo.

Primary outcome was quality of night sleep evaluated by Pittsburgh Sleep Quality Index (PSQI). The PSQI is a composite score constituting of seven components: 1) subjective sleep quality 2) sleep latency 3) sleep duration 4) sleep efficacy 5) sleep disturbance 6) use of sleep medication 7) and daytime dysfunction due to inadequate night sleep. Each component has a 0-3 scale with a total score of 0-21. A total PSQI score of greater than 5 manifests poor sleep quality with a sensitivity of 89.6% and specificity of 86.5% ([@CIT0027]). Since patients with the history of sedative-hypnotic medication use were excluded from the study, score of the sixth component was set as zero for all patients.

Secondary outcomes were daytime sleepiness and lung function and oxygenation. Daytime sleepiness was evaluated by Epworth Sleepiness Scale (ESS), a subjective questionnaire designed to determine the level of daytime sleepiness. Patients are asked to rate the probability of sleeping or dozing on a scale of increasing probability from 0 (none) to 3 (high probability) for eight different situations (sitting and reading, watching TV, sitting inactive in a public place, being a passenger in a vehicle for an hour without a break, lying down to rest in the afternoon whenever circumstances permit, sitting and talking to someone, Sitting quietly after a lunch without alcohol, sitting in a vehicle while stopped in traffic for a few minutes). Individual scores gained from these eight sections are then summed to produce a composite score. A total score of 10 or more is considered as excessive daytime sleepiness ([@CIT0028]).

Lung function and oxygenation were assessed by means of spirometry and pulse oximeter (Spirolab III , MIR company, Italy ) and for each patient FEV1, FVC, FEV1/FVC, FEF 25-75 and O~2~ saturation were calculated. After one month, evaluation of sleep quality, daytime sleepiness and lung function was repeated for all patients. Statistical analyses were performed using SPSS version 17.0 software for windows (SPSS Inc. Chicago, IL, USA). Continuous variables were expressed as mean ± standard deviation. Categorical variables (i.e. gender and smoking status) were presented as percentage. Independent t-test was employed to compare baseline measurements of continuous variables between melatonin and placebo groups. The efficacy of treatment modality within each group was assessed using paired t-test. To compare the effects of melatonin versus placebo after one month, analysis of variance (ANOVA) was conducted. In all tests, a p-value of less than 0.05 was considered statistically significant.

RESULTS {#S0003}
=======

A randomized double blind, placebo-controlled trial was conducted to assess the efficacy of melatonin administration in improving sleep quality in COPD patients. Initially, a total of 54 consecutive patients with stage II to IV COPD were enrolled and randomly assigned into either melatonin or placebo group. Six patients were excluded from the study; two patients from melatonin group experienced COPD exacerbation, four patients did not return for a follow up visit (two patients from each group). At the end of trial, 48 patients completed the protocol (23 from the melatonin group and 25 from the placebo group). There were no significant side effects in the two groups.

The mean age of the study participants was 66.32 ± 9.5 yrs. (range 46 to 83). Forty (83.3%) patients were men and 8 (16.7%) were women. Twenty-nine (60.4%) patients had a history of smoking.

Prior to treatment, there were no significant differences between the two groups in global PSQI scores, ESS scores, age, body mass index ([Table 1](#T0001){ref-type="table"}) and spirometry and oxygenation indices ([Table 3](#T0003){ref-type="table"}).

###### 

Baseline characteristics of the melatonin and placebo groups

             Melatonin    Placebo      P value
  ---------- ------------ ------------ ---------
  **Age**    65.7±9.34    66.85±9.62   0.658
  **BMI**    23.62±4.48   24.87±4.72   0.323
  **PSQI**   11.63±3.96   10.66±2.48   0.206
  **ESS**    7.04±4.43    6.33±3.5     0.530

BMI, body mass index; PSQI, Pittsburgh Sleep Quality Index; ESS, Epworth Sleepiness Scale.

###### 

PSQI (individual components and global score) before and after treatment in melatonin and placebo groups

                                                         Melatonin    Placebo      P value[a](#TF0001){ref-type="table-fn"}   P value[b](#TF0002){ref-type="table-fn"}
  ------------------------------------------ ----------- ------------ ------------ ------------------------------------------ ------------------------------------------
  **Sleep quality**                          Before      2±0.95       1.89±0.57    0.490                                      
  After                                      1.52±0.84   1.77±0.57                                                            
  P value[c](#TF0003){ref-type="table-fn"}   0.001       0.18                                                                 
  **Sleep latency**                          Before      2.22±0.95    2.04±0.89    0.494                                      
  After                                      1.74±1.17   1.74±0.86                                                            
  P value                                    0.001       0.23                                                                 
  **Sleep duration**                         Before      2.48±0.89    2.22±0.69    0.056                                      
  After                                      1.70±1.02   2.14±0.76                                                            
  P value                                    0.024       0.41                                                                 
  **Sleep efficacy**                         Before      2.30±1.06    2.11±1.05    0.522                                      
  After                                      1.61±1.27   2.03±1.12                                                            
  P value                                    0.003       0.15                                                                 
  **Sleep disturbance**                      Before      1.65±0.83    1.74±0.66    0.634                                      
  After                                      1.55±0.65   1.7±0.66                                                             
  P value                                    0.080       0.31                                                                 
  **Use of sleep medicine**                  Before      0            0            n/a                                        
  After                                      0           0                                                                    
  P value                                    0           0                                                                    
  **Daytime dysfunction**                    Before      0.91±0.85    0.63±0.84    0.178                                      
  After                                      0.78±0.67   0.7±0.91                                                             
  P value                                    0.180       0.157                                                                
  **Global Score**                           Before      11.63±3.96   10.66±2.48   0.206                                      
  After                                      8.7±4.15    10.11±2.66                \<0.001                                    
  P value                                    0.002       0.065                                                                

P value calculated for comparison of baseline differences between melatonin and placebo groups

P value calculated for comparison of treatment efficacy between melatonin and placebo groups

P value calculated for within group comparison (before and after treatment)

Abbreviations: PSQI, Pittsburgh Sleep Quality Index; n/a, not applicable

###### 

Spirometry indices and oxygen saturation before and after treatment in melatonin and placebo groups

                                                             Melatonin       Placebo         P value[a](#TF0004){ref-type="table-fn"}   P value[b](#TF0005){ref-type="table-fn"}
  ------------------------------------------ --------------- --------------- --------------- ------------------------------------------ ------------------------------------------
  **FEV1/FVC**                               Before          66.35 ± 6.31    62.67 ± 7.97    0.080                                      
  After                                      66.47 ± 6.46    63.04 ± 6.85                    0.273                                      
  P value[c](#TF0006){ref-type="table-fn"}   0.633           0.607                                                                      
  **FEV1 (%)**                               Before          47.04 ± 14.68   45.26 ± 14.81   0.672                                      
  After                                      47.52 ± 14.83   45.54 ± 15.17                   0.729                                      
  P value                                    0.077           0.423                                                                      
  **FVC (%)**                                Before          50.35 ± 14.01   48.74 ± 15.18   0.701                                      
  After                                      50.30 ± 14.43   48.92 ± 15.49                   0.841                                      
  P value                                    0.911           0.672                                                                      
  **FEF 25-75%**                             Before          38.65 ± 17.02   35.52 ± 16.76   0.516                                      
  After                                      38.80 ± 16.96   36.48 ± 16.70                   0.691                                      
  P value                                    0.426           0.081                                                                      
  **O** ~**2**~ **saturation (%)**           Before          91.52 ± 3.61    91.00 ± 3.44    0.607                                      
  After                                      91.91 ± 3.89    91.26 ± 2.82                    0.423                                      
  P value                                    0.131           0.336                                                                      

P value calculated for comparison of baseline differences between melatonin and placebo groups

P value calculated for comparison of treatment efficacy between melatonin and placebo groups

P value calculated for within group comparison (before and after treatment)

FEV1, forced expiratory volume at the end of first second; FVC, forced vital capacity; FEF, forced expiratory flow

[Table 2](#T0002){ref-type="table"} present PSQI global and sub domains score for study groups prior and after treatment. Global PSQI scores significantly improved in melatonin group after treatment (p=0.002). Comparing cases and controls, melatonin was superior to placebo in improving global PSQI score (p\<0.001). Among PSQI individual components, sleep quality (p=0.001), sleep latency (p=0.001), sleep efficacy (p=0.003), and sleep duration (p=0.024) improved significantly in cases after melatonin administration. On the other hand, melatonin treatment did not significantly change indices of daytime sleepiness, lung function or oxygen saturation (p\>0.05). Spirometry indices and oxygen saturation before and after treatment are presented in [Table 3](#T0003){ref-type="table"}.

DISCUSSION {#S0004}
==========

In this study 48 patients with stage II to IV COPD were investigated in a randomized clinical trial to reveal the effect of melatonin administration on sleep quality. Our results corroborate the results of previous studies. Shilo et al, ([@CIT0029]) for the first time evaluated the effects of melatonin on improvement of sleep quality in COPD patients. They studied eight patients in pulmonary ICU with exacerbation of COPD; sleep quality was assessed using wrist actinography. They observed a significant improvement in sleep quality and sleep duration after melatonin treatment. They recommended melatonin administration for sleep induction and resynchronization of biological clock in ICU patients. In contrast to Shilo et al, our study participants were in ambulatory condition and had not experienced exacerbation episodes at least in the past month. Thus, melatonin has beneficial effects on both outpatients and inpatients. Nunes et al. ([@CIT0030]) also used melatonin administration to resolve sleep disturbances in COPD patients. Similar to our study, PSQI was used to evaluate sleep quality. Additionally, daytime sleepiness, pulmonary function and functional exercise level were measured using ESS, spirometry and the 6-minute walk test, respectively. After melatonin prescription, global PSQI scores significantly improved compared with the placebo group. However, no significant differences were observed in other variables. Nunes et al. used melatonin in all COPD patients but we used this drug in COPD patients with sleep disturbances (PSQI \>5). Melatonin is administered to treat poor sleep quality; therefore, selection of these patients is reasonable. Also Nunes et al. ([@CIT0030]) showed that melatonin had no effect on sleep latency but in our study sleep latency decreased clearly. Thus, it seems that melatonin consumption could accelerate the onset of sleep. In another study by Campos et al. ([@CIT0031]) effects of melatonin administration on improvement of sleep quality and pulmonary function in asthma patients were investigated. They concluded that melatonin significantly improved sleep quality but had no significant effects on peak flow and asthma symptoms. In our study melatonin had no sizeable effects on spirometry parameters such as FEV1, FVC, FEV1/FVC and FEF 25-75.

As stated earlier, melatonin has long been used for treatment of certain insomnia and regulation of circadian rhythm sleep disorders (CRSDs) ([@CIT0032]). For instance, Zhdanova et al. in a series of studies revealed that melatonin administration in healthy individuals reduces sleep latency and results in improved sleep efficacy ([@CIT0033], [@CIT0034]). Melatonin levels drop with advanced age ([@CIT0035], [@CIT0036]), and it has been hypothesized that this decrement is a principal cause for poor sleep quality and sleep disturbance in the elderly. Garfinkel et al. ([@CIT0037]) demonstrated that melatonin administration improves sleep efficiency in the elderly population. Moreover, a number of brain pathologies, such as Alzheimer\'s disease are associated with decrease in melatonin levels and resultant sleep disturbances; beneficial effects of exogenous melatonin on these patients have been proven in different studies ([@CIT0038]--[@CIT0040]). Safety issues in melatonin administration have also been thoroughly assessed. A recent meta-analysis showed the safety of short-term administration of melatonin ([@CIT0041]). Our observations confirmed the previous results and no major side effects were reported in patients receiving melatonin.

Mechanisms by which melatonin exerts its main effects remain largely unknown. Recent evidence indicates that melatonin, when secreted in its physiological dose, is able to interrupt circadian rhythm that maintains insomnolence via a receptor-mediated pathway ([@CIT0022]).

In conclusion, wide range of therapeutic use of melatonin in treatment of sleep disturbances reveals the efficacy of this agent and the potential use of melatonin for improving sleep quality in COPD patients with sleep complaints.
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